Giuliani consolidates acquisitions in 2026 and aims for 250 million turnover

The pharmaceutical company Giuliani consolidates the business after the latest acquisitions and aims to have the set-up of an international healthcare group with different areas of specialisation from gastroenterology to dermatology, trichology, dietary supplementation and special nutrition.

This year, the company headed by the family of the same name will reach the milestone of 250 million in turnover, and just yesterday it received a stamp from the Ministry of Enterprise and Made in Italy in the series 'Le Eccellenze del sistema produttivo e del Made in Italy'. It is an acknowledgement of a family, scientific and industrial history over 130 years long, given that the group was founded in Milan in 1889 in the Antica Farmacia del Lazzaretto. The stamp, as Giammaria Giuliani, the Group's main shareholder together with his brother Mario Germano Giuliani and representative of the fourth generation of the family, explains, "is a source of great pride for us because it recognises not only an entrepreneurial history of over 130 years, but also Giuliani's ability to remain faithful to its identity by transforming it into a contemporary industrial project. Our roots are in the Italian pharmaceutical tradition, but our gaze is turned towards the future: research, innovation, quality and international growth are the principles that guide our family and our company". "Seeing Giuliani represented on a postage stamp of the Italian State is an acknowledgement that belongs to all the generations of the family that have contributed to building the company, as well as to those who continue its development today. It is also an incentive to continue to make Giuliani grow as an Italia group that is increasingly competitive on international markets," adds Giammaria Giuliani.

In recent years, Giuliani has accelerated its growth path through an industrial design based on the aggregation of complementary competences. Just to mention the most recent major additions, in 2021 it acquired Nathura, thus strengthening its nutraceutical and gastrointestinal area, in 2023 it acquired Biogena, with which it strengthened its dermatological division, and finally in 2025 the Laboratoires Bailleul transaction strengthened the company's position in the therapeutic areas of greatest interest and, above all, brought it a pan-European platform with its own subsidiaries in various countries, significantly expanding the Group's international presence. Between internal and external growth, Giuliani will reach a turnover of EUR 250 million this year. "These combinations represent a key step in Giuliani's evolution," Giammaria Giuliani continues, "from a historic pharmaceutical company to an integrated healthcare group, with an increasingly strong presence in specialised therapeutic areas. Our strategy is to build critical mass in the segments in which we operate, to enhance assets with high scientific content, and to integrate research, medical-scientific marketing, and commercial development skills. We want to further strengthen our relationship with doctors, pharmacists, patients and consumers, leveraging recognised brands, distinctive competencies and a growing international network'.